Treatment of Lupus Nephritis with anti-CD20 Followed by Anti-BAFF: Impact on B Cell Reconstitution, B Cell Subsets, and Autoreactivity

被引：0
|
作者：
Fregoso, Yemil Atisha [1 ]
Malkiel, Susan [1 ]
Harris, Kristina [2 ]
Kanaparthi, Sai [2 ]
Byron, Margie [3 ]
Ding, Linna [4 ]
Smilek, Dawn [5 ]
Wofsy, David [6 ]
Dall'Era, Maria [7 ]
Aranow, Cynthia [1 ]
Diamond, Betty [1 ]
机构：
[1] Feinstein Inst Med Res, Manhasset, NY USA
[2] Immune Tolerance Network, Bethesda, MD USA
[3] Rho Fed Syst Inc, Chapel Hill, NC USA
[4] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA
[5] Immune Tolerance Network, San Francisco, CA USA
[6] UCSF, San Francisco, CA USA
[7] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2019年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0941
引用
收藏
页数：4
相关论文
共 50 条
  • [31] B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience
    Shaw, T
    Quan, J
    Totoritis, MC
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 55 - 59
  • [32] Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
    Sun, Liping L.
    Ellerman, Diego
    Mathieu, Mary
    Hristopoulos, Maria
    Chen, Xiaocheng
    Li, Yijin
    Yan, Xiaojie
    Clark, Robyn
    Reyes, Arthur
    Stefanich, Eric
    Mai, Elaine
    Young, Judy
    Johnson, Clarissa
    Huseni, Mahrukh
    Wang, Xinhua
    Chen, Yvonne
    Wang, Peiyin
    Wang, Hong
    Dybdal, Noel
    Chu, Yu-Waye
    Chiorazzi, Nicholas
    Scheer, Justin M.
    Junttila, Teemu
    Totpal, Klara
    Dennis, Mark S.
    Ebens, Allen J.
    SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (287)
  • [33] B-cell depletion by anti-CD20 antibody treatment in rheumatoid arthritis modulates the B-cell repertoire.
    Rouzière, AS
    Kneitz, C
    Dörner, T
    Tony, HP
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S138 - S138
  • [34] Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies
    Gupta, Ira V.
    Jewell, Roxanne C.
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2011, 2012, 1263 : 43 - 56
  • [35] An anti-CD20 extracellular antibody-drug conjugate for the treatment of B-cell malignancies
    Prudent, James R.
    Hall, Chad A.
    Marshall, David J.
    Murphy, John
    Harried, Scott
    CANCER RESEARCH, 2016, 76
  • [36] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    R Eisenberg
    D Albert
    J Stansberry
    D Tsai
    S Kolasinski
    S Khan
    Arthritis Res Ther, 5
  • [37] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    Eisenberg, R
    Albert, D
    Stansberry, J
    Tsai, D
    Kolasinski, S
    Khan, S
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S9 - S10
  • [38] RADIOIMMUNOTHERAPY OF B-CELL LYMPHOMA WITH [I-131] ANTI-B1 (ANTI-CD20) ANTIBODY
    KAMINSKI, MS
    ZASADNY, KR
    FRANCIS, IR
    MILIK, AW
    ROSS, CW
    MOON, SD
    CRAWFORD, SM
    BURGESS, JM
    PETRY, NA
    BUTCHKO, GM
    GLENN, SD
    WAHL, RL
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (07): : 459 - 465
  • [39] RADIOIMMUNOTHERAPY OF REFRACTORY B-CELL LYMPHOMA WITH 131-I-ANTI-B1 (ANTI-CD20) ANTIBODY
    KAMINSKI, MS
    FENNER, M
    ZASADNY, KR
    MILIK, AW
    ROSS, CW
    FRANCIS, IR
    BURGESS, J
    ESTES, J
    CRAWFORD, S
    HODUL, P
    COOK, R
    REGAN, D
    PETRY, N
    GLENN, S
    BUTCHKO, G
    WAHL, RL
    CLINICAL RESEARCH, 1994, 42 (03): : A405 - A405
  • [40] (90)Yttrium labeled anti-CD20 therapy for recurrent B cell lymphoma
    Davis, TA
    Goris, ML
    Trisler, KD
    Negrin, R
    Liles, TM
    Fowler, SF
    Deb, N
    Becker, M
    Marquez, CM
    Ning, S
    Levy, R
    Knox, S
    BLOOD, 1995, 86 (10) : 1080 - 1080
12345